NIH-funded research R01 grant

Biomarkers to Guide Early Treatment in First-Episode Psychosis (BEEST)

Official title: 1/5 Biomarkers to Enhance Early Schizophrenia Treatment (BEEST)

Funded at Centre for Addiction and Mental Health · NIH-11405513 · Data updated 2026-11-12

A multi-center study aims to use brain scans and genetic information to help teens and young adults with a first episode of psychosis choose the best antipsychotic sooner.

More Schizophrenia research and trials

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionCentre for Addiction and Mental Health
NIH-funded
Lab location1 site (Toronto, Canada)
Project startSeptember 5, 2024
Project endJuly 31, 2029
Funding year2026
Award (this year)$289,948
NIH project number5R01MH134889-03
Project IDNIH-11405513 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates are adolescents and young adults experiencing a first episode of psychosis who may require antipsychotic therapy.

Less likely to help

Patients with conditions unrelated to first-episode psychosis or those not expected to need clozapine-based decision making may not benefit.

What this research studies

This project focuses on teens and young adults experiencing their first episode of psychosis. It will use brain imaging and genetic tests to predict who might not respond to typical first-line antipsychotic drugs and who might be at higher risk of weight gain or agranulocytosis. Based on these biomarker results, researchers will work toward a decision-support tool to guide clozapine use when appropriate, with the goal of improving outcomes. The study plans to enroll about 410 participants across multiple centers and collect standardized biomarker data to harmonize findings.

Why it matters

Potential benefit: If successful, patients could receive more effective, personalized treatment earlier, potentially reducing disability and side effects.

How similar studies have gone: Previous work suggests biomarkers can help predict response to antipsychotics and guide treatment, but this approach is still being tested for broader clinical use.

Where this research is happening

  • Centre for Addiction and Mental Health
    Toronto, Canada
    Active

Researchers

  • Principal investigator: Voineskos, Aristotle Nicholas — Centre for Addiction and Mental Health
  • Study coordinator: Voineskos, Aristotle Nicholas

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.